Cardiology Today -- Rosuvastatin successfully lowered LDL levels and demonstrated a favorable safety profile after one year among children aged 10 to 17 years who had familial hypercholesterolemia, findings from the PLUTO trial indicated.
Cardiology Today -- Rosuvastatin successfully lowered LDL levels and demonstrated a favorable safety profile after one year among children aged 10 to 17 years who had familial hypercholesterolemia, findings from the PLUTO trial indicated.